GlobeNewsWire
24 Sept 2025, 20:05 UTC · 51w ago
Verdict
Headline takes no side. We score VRNA +1.00 across two claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Verona Pharma shareholders have approved Merck's acquisition of the company for $107 per ADS, valuing the total transaction at approximately $10 billion.
More positive than 98% of claims this week
The transaction is expected to close on October 7, 2025, pending a court hearing scheduled for October 6, 2025.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 64% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Shareholders approved a $10 billion acquisition, providing a significant premium for shareholders.
More positive than 50% of ticker scores this week
Company is expanding its portfolio through the strategic acquisition of a respiratory-focused biopharmaceutical firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
22h ago
+0.5%
Price flat so far
$106.91 vs $106.39 close before publication (Sep 24) · not market-adjusted
VRNA chart →
